Short DAPT Wins, Ultra-Short Fails 🚫1️⃣✅3️⃣ Stratified Strategy From HOST-BR
Dr RR Baliga's "Got Knowledge Doc" Podkast
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
🫀 Personalizing DAPT: When "One Size Fits All" Fails 🕊️💊
The HOST-BR trial in The Lancet offers an important clinical lesson:
Bleeding risk should guide antiplatelet duration after PCI — not habit, not inertia.
🔍 Key insight
-
In ARC-HBR patients, 1-month DAPT was not non-inferior to 3 months
-
In non-HBR patients, 3-month DAPT was non-inferior to 12 months and reduced bleeding
🧠 Clinical takeaway
➡️ Ultra-short (1-mo) DAPT is risky in high-bleeding-risk patients
➡️ Short (3-mo) DAPT is safe and bleeding-sparing in lower-risk patients
🔧 Precision medicine in action:
Stratify → Tailor → Protect
📎 HOST-BR | The Lancet (2025)
A beautiful reminder that medicine advances when we match therapy to physiology — not the other way around.
🌟 "Do no harm" is evolving… now it means do no unnecessary bleeding.
#Cardiology #InterventionalCardiology #PrecisionMedicine #DAPT #PCI #BleedingRisk #Lancet